Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0KJKBV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Trastuzumab (C2) |
|||||
| Organization | Technical University of Darmstadt.; University of Bielefeld.; Lantern Pharma Inc.; The University of Tennessee.; Technical University of Darmstadt. |
|||||
| Synonyms |
Trastuzumab (C2)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG1 |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Tras (C2)-Cp [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
59䔮 pM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1208𫔬 pM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
References